From "Ought" to "Is": Surfacing Values in Patient and Family Advocacy in Rare Diseases

Affiliations

Comment

Meghan C Halley. Am J Bioeth. 2021 Dec.

. 2021 Dec;21(12):1-3.

doi: 10.1080/15265161.2021.1996801.

No abstract available

Comment on

Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?
Lynch HF, Caplan A, Furlong P, Bateman-House A. Lynch HF, et al. Am J Bioeth. 2021 Dec;21(12):4-19. doi: 10.1080/15265161.2021.1974975. Epub 2021 Oct 19. Am J Bioeth. 2021. PMID: 34665689
Decisions on Innovation or Research for Devastating Disease.
Andreae MH, Shah LD, Shepherd V, Sheehan M, Sacks HS, Rhodes R. Andreae MH, et al. Am J Bioeth. 2021 Dec;21(12):28-31. doi: 10.1080/15265161.2021.1991042. Am J Bioeth. 2021. PMID: 34806956 No abstract available.
Physician Responsibility to Discuss Palliative Unproven Therapies With Out-of-Option Patients.
Kawam O, Tilburt JC, Master Z. Kawam O, et al. Am J Bioeth. 2021 Dec;21(12):31-33. doi: 10.1080/15265161.2021.1991038. Am J Bioeth. 2021. PMID: 34806967 Free PMC article. No abstract available.
Another Cautionary Lesson from COVID Research.
Grady C. Grady C. Am J Bioeth. 2021 Dec;21(12):36-39. doi: 10.1080/15265161.2021.1991048. Am J Bioeth. 2021. PMID: 34806970 Free PMC article. No abstract available.

1. Andreae MH, Shah L, Shepherd V, Sheehan M, Sacks HS, and Rhodes R. 2021. Bias and noise cloud decision-making on innovation versus research in devastating disease. The American Journal of Bioethics. 21 (12):28–31. doi: 10.1080/15265161.2021.1991042. - DOI - PubMed
1. Best RK 2012. Disease politics and medical research funding: three ways advocacy shapes policy. American Sociological Review 77 (5):780–803. doi: 10.1177/0003122412458509. - DOI
1. Cook-Deegan R 2006. Chapter 8. The jewel in the federal crown? History, politics, and the National Institutes of Health. In History and health policy in the United States: Putting the past back in, 176–201. New Brunswick, NJ: Rutgers University Press. doi: 10.36019/9780813539874-011. - DOI
1. Dunkle M, Pines W, and Saltonstall PL. 2010. Advocacy groups and their role in rare diseases research. In Rare diseases epidemiology, ed. de la Paz Manuel Posada and Groft Stephen C., 515–525. Advances in experimental medicine and biology. Dordrecht: Springer Netherlands. doi: 10.1007/978-90-481-9485-8_28. - DOI - PubMed
1. Grady C 2021. Another cautionary lesson from COVID research. The American Journal of Bioethics. 21 (12): 36–39. doi: 10.1080/15265161.2021.1991048. - DOI - PMC - PubMed